Clinic Roundup

StemCells Inc., of Palo Alto, Calif., started a Phase I/II trial of its HuCNS-SC human neural stem cells in chronic spinal cord injury in patients with both complete and incomplete degrees of paralysis who are three months to 12 months post-injury. The study will enroll 12 patients in three cohorts with thoracic spinal cord injuries who have a neurological injury level of T2-T11.